Copy
View this email in your browser
JCR Pharmaceuticals
New Treatment Award

ISMRD would like to congratulate JCR Pharmaceuticals for its WORLDSymposium™ 2022 New Treatment Award.  The award will be presented to JCR Pharmaceuticals  for pabinafusp alfa (IZCARGO®), which provided clinical data meriting approval by the Ministry of Health, Labour and Welfare in Japan.  Pabinafusp alfa is the first approved Enzyme Replacement Therapy for MPS II (Hunter Syndrome) to penetrate the Blood-Brain Barrier via intravenous administration. This is an important achievement in therapy for lysosomal diseases for attaining regulatory approval.

The New Treatment Award will be presented to JCR Pharmaceuticals on Thursday, February 10, 2022, at the  18th Annual WORLDSymposium™ 2022 in San Diego.

Well done, JCR Pharmaceuticals

Share Share
Tweet Tweet
Forward Forward
Twitter
Facebook
Website
Contact Us
ISMRD
The International Advocate for Glycoprotein Storage Diseases
20880 Canyon View Drive
Saratoga, CA, 95070
USA
E-mail: info@ismrd.org

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.
Twitter
Facebook
Website
Contact Us
ISMRD
The International Advocate for Glycoprotein Storage Diseases
20880 Canyon View Drive
Saratoga, CA, 95070
USA
E-mail: info@ismrd.org

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.






This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
ISMRD · 20880 Canyon View Drive · Saratoga, Ca 95070 · USA

Email Marketing Powered by Mailchimp